Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  August 2019  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
     1  2  3  4
  5  6  7  8  91011
121415161718
19202122232425
262728293031 

Latest IDIGH Publications

  1. Lénárt, A., Engler, K., Lessard, D., Toupin, I., Rodríguez, C. & Lebouché, B.
    (2019)
    .
    The involvement of people living with HIV in the development of HIV-specific or inclusive health instruments: a mixed methods review
    .
    AIDS care
    ,
    p
    .
    1-10
    .
  2. Jung, S. & Vinh, D. C.
    (2019)
    .
    Disseminated Pruritic Macules in a Solid Organ Transplant Recipient
    .
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
    ,
    vol
    .
    69
    ,
    p
    .
    897-899
    .
  3. Bamford, N. C., Le Mauff, F., Subramanian, A. S., Yip, P., Millán, C., Zhang, Y., Zacharias, C., Forman, A., Nitz, M., Codée, J. D. C., Usón, I., Sheppard, D. C. & Howell, P. L.
    (2019)
    .
    Ega3 from the fungal pathogen Aspergillus fumigatus is an endo-α-1,4-galactosaminidase that disrupts microbialbiofilms
    .
    The Journal of biological chemistry
  4. Adams, S., Ehrlich, R., Baatjies, R., Dendukuri, N., Wang, Z. & Dheda, K.
    (2019)
    .
    Evaluating Latent Tuberculosis Infection Test Performance Using Latent Class Analysis in a TB and HIV Endemic Setting
    .
    International journal of environmental research and public health
    ,
    vol
    .
    16
  5. Sabri, A., Quistrebert, J., Naji Amrani, H., Abid, A., Zegmout, A., Abderrhamani Ghorfi, I., Souhi, H., Boucaid, A., Benali, A., Abilkassem, R., Kmari, M., Hassani, A., Lahcen, B., Siah, S., Schurr, E., Boisson-Dupuis, S., Casanova, J.-L., Lahlou, A., Laatiris, A., Louzi, L., Ouarssani, A., Bourazza, A., Aouragh, A., Mustapha, B., Messaoudi, N., Agader, A., Cobat, A., Abel, L. & El Baghdadi, J.
    (2019)
    .
    Prevalence and risk factors for latent tuberculosis infection among healthcare workers in Morocco
    .
    PloS one
    ,
    vol
    .
    14
    ,
    p
    .
    e0221081
    .
More publications